Evidence-based medicine forms the backbone of contemporary pain practice. Randomized controlled trials (RCTs), systematic reviews, and clinical guidelines increasingly dictate which interventional pain procedures are recommended and reimbursed. Yet, a persistent and widely acknowledged paradox remains: interventions supported by strong evidence frequently underperform or fail altogether in routine clinical practice. This disconnect between trial efficacy and real-world effectiveness is not an indictment of evidence-based pain medicine, but rather a reflection of its incomplete translation into complex clinical realities. This editorial explores the key reasons why evidence-based pain interventions fail in real-world practice and argues that these failures arise primarily from limitations in patient selection, pain phenotyping, contextual application, and overgeneralization of evidence. The Fallacy of the “Average Patient” RCTs are designed to optimize internal validity by minimizing confounders. As a result, study populations are often highly selected, excluding patients with psychiatric comorbidity, multisite pain, opioid dependence, compensation issues, or previous interventional failures. While methodologically sound, this creates a trial population that differs substantially from patients encountered in daily pain practice. In real-world settings, patients commonly present with overlapping pain generators, mixed pain mechanisms, psychosocial distress, and long-standing pain. Applying evidence generated from relatively homogeneous trial populations to such heterogeneous patients inevitably leads to reduced effectiveness. The problem is not that the intervention lacks efficacy, but that the patient does not resemble the population in which that efficacy was demonstrated. This fundamental mismatch is one of the most important drivers of real-world failure.1 Inadequate Pain Phenotyping Pain is no longer understood as a purely nociceptive phenomenon. Contemporary models recognize that chronic pain frequently represents a combination of nociceptive, neuropathic, and nociplastic mechanisms.2 Despite this, many interventional pain trials—and much of routine clinical decision-making—remain structurally oriented rather than mechanism driven. Patients labeled with anatomically defined conditions such as facet joint pain or sacroiliac joint pain often have substantial central sensitization or nociplastic dominance. In such cases, peripheral interventions may be technically successful yet clinically ineffective. Without systematic pain phenotyping, evidence-based interventions are frequently applied to patients whose dominant pain mechanism is not amenable to the chosen procedure. This mismatch between mechanism and intervention is a major contributor to treatment failure.3 Diagnostic Blocks: Useful but Imperfect Diagnostic blocks play a central role in patient selection for many interventional procedures. However, their limitations are well recognized. False-positive responses may occur due to placebo effects, nonspecific anesthetic spread, or transient modulation of central pain processing. Conversely, false-negative responses may arise in patients with multifactorial pain or significant central sensitization.4,5 RCTs often treat diagnostic blocks as reliable gatekeepers for intervention eligibility. In clinical practice, however, overreliance on block response without integrating clinical history, pain behavior, functional limitation, and longitudinal response increases the likelihood of inappropriate intervention selection. Diagnostic blocks should be viewed as adjuncts to clinical reasoning, not as definitive arbiters of pain generators. Technical Success is not Clinical Success Another critical factor underlying real-world failure is the assumption that technical success guarantees clinical benefit. Interventional trials are typically performed by expert operators using standardized techniques under controlled conditions. In routine practice, procedural variability is unavoidable and may significantly influence outcomes. More importantly, even when technical execution is optimal, biological variability plays a decisive role. Differences in neural plasticity, inflammatory response, and pain modulation determine whether interrupting a presumed pain pathway translates into meaningful relief. Pain is not purely mechanical; it is a dynamic neurobiological process.6 Failure to distinguish technical success from biological success often leads to unrealistic expectations of interventional outcomes. The Role of Pain Chronicity and Centralization Pain duration is one of the most underappreciated determinants of interventional effectiveness. As pain becomes chronic, peripheral nociceptive drivers increasingly give way to central sensitization and maladaptive neuroplastic changes.6,7 Many interventional trials do not adequately stratify patients based on pain duration or degree of centralization. In real-world practice, interventions supported by evidence in acute or subacute pain are often applied to patients with long-standing chronic pain, where the underlying biology has fundamentally changed. When interventions are performed late in the pain chronification continuum, failure is more likely—not because the evidence is incorrect, but because the biological substrate is no longer responsive. Outcome Measures and the Meaning of Success RCTs rely on standardized outcome measures such as numerical pain scores or disability indices. While necessary for research comparability, these measures do not always reflect outcomes that matter most to patients. In clinical practice, patients often prioritize functional improvement, reduced medication dependence, improved sleep, or enhanced coping over numerical pain reduction. An intervention may meet trial-defined success thresholds yet still be perceived as a failure by the patient—or the clinician. Conversely, modest pain reduction accompanied by functional gains may represent meaningful success in real-world settings. This disconnect between trial endpoints and patient-centered outcomes contributes to the perceived failure of evidence-based interventions.8 Expectation and Contextual Influences Patient expectations exert a powerful influence on pain outcomes. Unrealistic expectations of complete pain elimination, previous negative healthcare experiences, and misinformation are common in routine practice but tightly controlled or minimized in clinical trials. Contextual factors such as compensation claims, litigation, occupational dissatisfaction, and psychosocial stress—often excluded from trials—can significantly modulate treatment response.8,9 Failure to address expectations and contextual influences can convert partial benefit into perceived failure. Evidence-based interventions do not operate in a vacuum; their effectiveness is shaped by the environment in which they are delivered. Guidelines are not Clinical Pathways Clinical guidelines synthesize evidence but are not designed to manage complexity. They answer the question of what works, but often fail to clarify for whom, when, and in what sequence. In real-world practice, pain physicians require adaptive clinical pathways that integrate pain mechanisms, chronicity, comorbidities, and longitudinal reassessment. When guideline-endorsed interventions are applied as isolated events rather than as components of an integrated management strategy, real-world effectiveness diminishes. Guidelines should inform, not replace, clinical judgment. Overgeneralization and Evidence Drift A further contributor to failure is the tendency to extrapolate evidence beyond its original scope. Interventions validated for specific pain conditions are frequently applied to broader indications without equivalent supporting data. Such overgeneralization dilutes the predictive value of evidence and increases failure rates. Evidence must define boundaries as clearly as it defines indications. Knowing when not to intervene is as critical as knowing when to do so.10 Toward a Pragmatic Model of Evidence-Based Pain Practice The limitations discussed do not argue against evidence-based pain medicine; rather, they highlight the need for its evolution. A pragmatic approach to evidence application should emphasize: Mechanism-based pain phenotyping. Context-aware patient selection. Consideration of pain chronicity and central sensitization. Integration of interventions within longitudinal care plans. Evidence should guide clinical reasoning, not substitute for it. Conclusion Evidence-based pain interventions fail in real-world practice not because the evidence is flawed, but because it is often applied without sufficient attention to patient complexity, pain mechanisms, chronicity, expectations, and context. Bridging the gap between trial efficacy and clinical effectiveness requires moving beyond rigid adherence to evidence toward thoughtful integration of evidence with individualized clinical judgment. In pain medicine, success rarely lies in a single procedure. It emerges from the intelligent synthesis of evidence, experience, and patient-centered reasoning. Acknowledgments The authors acknowledge the academic and clinical environment of Daradia: The Pain Clinic, which supported the development of this editorial. Author contributions Conceptualization: GD. Writing—original draft: GD. Writing—review and editing: SD, MJ. Critical intellectual input: All authors. Final approval of manuscript: All authors. Ethical policy and Institutional Review board statement Not applicable. This editorial does not involve human participants, patient data, or identifiable information. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
Das et al. (Thu,) studied this question.